C2CD5

Across TCGA pan-cancer cohorts, C2CD5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C2CD5 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C2CD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated C2CD5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and COAD are the cancer types where C2CD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	1.000	0.731	.001	42	view →
LSCC	DFS	Tertile	All	1.000	0.922	.002	24	view →
COAD	DFS	Median	All	1.000	0.891	.026	18	view →
GBM	DFS	Tertile	All	0.856	0.598	.003	18	view →
CCRCC	DFS	Tertile	III,IV	0.904	0.123	.024	5	view →
HNSC	OS	Tertile	All	0.770	0.877	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C2CD5–PDAC (OS)

Open the PDAC breakdown →